Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia

Authors
Category Primary study
JournalBlood
Year 2023
This article has no abstract
Epistemonikos ID: cd9122cf9eeccc1b5fc253fd1bcafab7f7ccfa84
First added on: Feb 17, 2025